Last reviewed · How we verify
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
This is a single institution phase II study of a reduced intensity conditioning (RIC) followed by a haploidentical hematopoietic cell transplant (haplo-HCT) in persons with diagnosis of hematologic malignancy. Conditioning will consists of fludarabine, cyclophosphamide, melphalan and total body irradiation (TBI) preparative regimen with a melphalan dose reduction for patients ≥55 years old and those with HCT Comorbidity Index (CI) \>3. This study uses a two-stage phase II design with accrual goal of 84 patients, using 28 patients separately for arms A, C and D
Details
| Lead sponsor | Masonic Cancer Center, University of Minnesota |
|---|---|
| Phase | PHASE2 |
| Status | COMPLETED |
| Enrolment | 78 |
| Start date | Tue Jan 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Mar 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Hematologic Malignancies
Interventions
- Haplo HCT <55 years old
- Haplo HCT ≥55 years old
- GVHD Prophylaxis
- Haplo HCT ≥55 and < 65 years old
- Haplo HCT ≥65 and ≤75 years old
Countries
United States